Advanced Biofuels USA: promoting the understanding, development and use of advanced biofuels around the world.

Call to Action for a Truly Sustainable Renewable Future
August 8, 2013 – 5:07 pm | No Comment

-Include high octane/high ethanol Regular Grade fuel in EPA Tier 3 regulations.
-Use a dedicated, self-reducing non-renewable carbon user fee to fund renewable energy R&D.
-Start an Apollo-type program to bring New Ideas to sustainable biofuel and …

Read the full story »
Business News/Analysis

Federal Legislation

Political news and views from Capitol Hill.

More Coming Events

Conferences and Events List in Addition to Coming Events Carousel (above)

Original Writing, Opinions Advanced Biofuels USA


Home » Business News/Analysis, Patent and Trademark Office

Butamax Granted Biobutanol DHAD Enzyme Patent 8,241,878; Files Additional Lawsuit against Gevo for Patent Infringement

Submitted by on August 15, 2012 – 4:00 pmNo Comment

(Butamax)  Butamax™ Advanced Biofuels, LLC, the biobutanol technology leader, announced today the United States Patent and Trademark Office (USPTO) has granted Butamax™ Patent Number 8,241,878. This patent provides early protection for high activity enzymes that perform a key a step in the pathway for making isobutanol.

“Butamax was first to identify the superior activity of these DHAD enzymes for the production of isobutanol,” said Paul Beckwith, Butamax CEO, “and we are pleased to add this patent to our extensive intellectual property portfolio.” These DHAD enzymes perform the third of the five steps in the engineered isobutanol biosynthetic pathway invented by Butamax.

Butamax filed an additional lawsuit against Gevo today for infringement of this patent. Butamax continues to vigorously defend its patent rights and seeks expedited proceedings to stop Gevo’s ongoing infringement. The priority dates of Butamax’s foundational and subsequent patents, including the ‘878 patent, demonstrate that Butamax innovated the key technology for isobutanol production years before Gevo patents were filed. In fact, Butamax’s priority for the ‘878 patent is well before Gevo filings related to DHAD enzymes.

In related news, the Federal Circuit has granted Butamax’s request for an expedited appeal of the recent preliminary injunction decision. Butamax’s enforcement activities, including the expedited appeal, are solely intended to protect its pioneering position and its patent rights.

Briefing under the expedited appeal is to be completed in September at which time a hearing will be scheduled. Butamax expects a favorable decision in early 2013. In the meantime, the Federal Circuit has granted a stay, pending appeal, of the injunction recently issued against Gevo.  READ MORE

Tags: , , ,

Comments are closed.